FDA Approves KEYTRUDA and KEYTRUDA QLEX for Muscle-Invasive Bladder Cancer
The FDA has approved KEYTRUDA and KEYTRUDA QLEX in combination with Padcev for MIBC treatment before and after surgery.
Therapeutic Area
Therapeutic area intelligence for PD-1 Inhibitor and ADC with 1 indexed intelligence signal across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
No related entities indexed yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.